Dublin, Sept. 08, 2026 (ZM NEWSWIRE) — The “Pipeline of Claudin 18.2-Targeted Immunotherapy” has been added to ResearchAndMarkets.com’s offering.
This competitive intelligence report provides an up-to-date assessment of the global Claudin-18.2 targeted immunotherapeutics market and development pipeline. Prepared on demand within one working day of order placement, the report evaluates active research and development programs targeting claudin 18.2 (CLDN18.2), with candidates organized by clinical development phase in a structured tabular format. It also presents concise profiles of anti-CLDN18.2 immunotherapy candidates segmented by drug modality.
CLDN18.2 is selectively expressed in normal gastric mucosa and retained in many gastric and gastroesophageal junction (G/GEJ) adenocarcinomas. Malignant transformation and loss of cell polarity can increase CLDN18.2 accessibility, supporting its development as a therapeutic target. The growing clinical validation of this target has accelerated investment in CLDN18.2-targeted monoclonal antibodies, antibody-drug conjugates, cellular therapies, bispecific antibodies and other next-generation immuno-oncology platforms.
Zolbetuximab is a first-in-class immunoglobulin G1 monoclonal antibody designed to target CLDN18.2 and mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in CLDN18.2-positive G/GEJ adenocarcinoma cells. Marketed as VYLOY (zolbetuximab-clzb), it is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors are CLDN18.2 positive.
Zolbetuximab has received approvals in major markets, including Japan, the United Kingdom, South Korea, the United States, Canada, Brazil and China. It has also received European Commission marketing authorization, which applies across all 27 European Union member states, as well as Iceland, Liechtenstein and Norway. These approvals have established zolbetuximab as the principal clinical and commercial benchmark for follow-on CLDN18.2 targeted therapies.
The pivotal Phase III SPOTLIGHT and GLOW trials demonstrated statistically significant and clinically relevant improvements in progression-free survival and overall survival. Progression-free survival improved by 1.94 months in SPOTLIGHT and 1.41 months in GLOW, while overall survival improved by 2.69 months and 2.23 months, respectively. Frequently reported adverse events included nausea, vomiting and decreased appetite.
Patient eligibility remains an important consideration for CLDN18.2 targeted treatment. In the zolbetuximab clinical program, 39.1% of screened gastric cancer patients met the relevant biomarker criteria. Eligibility required moderate-to-strong membranous CLDN18 staining in at least 75% of tumor cells, highlighting the importance of diagnostic testing, biomarker thresholds and patient-selection strategies in future CLDN18.2 drug development.
The limitations and clinical profile of zolbetuximab have created opportunities for next-generation CLDN18.2 immunotherapies with enhanced potency, broader patient eligibility, improved tolerability and more durable antitumor activity. Development programs covered in the report include:
- Naked monoclonal antibodies engineered for higher target affinity and increased antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis.
- CLDN18.2 antibody-drug conjugates incorporating advanced linker technologies, optimized conjugation methods and novel cytotoxic payloads.
- Chimeric antigen receptor T-cell and natural killer cell therapies featuring improved signaling domains, armored constructs and modular designs.
- Bispecific T-cell engagers and T-cell-engaging antibodies designed to recruit cytotoxic T cells against CLDN18.2-expressing tumors.
- Bispecific immuno-oncology antibodies targeting CLDN18.2 alongside pathways or receptors such as PD-L1, 4-1BB, CD47/SIRP? and CD8.
By consolidating active CLDN18.2 clinical trials, emerging therapeutic modalities, development stages and competitive profiles, this report supports strategic planning, pipeline benchmarking, licensing assessments, partnering initiatives and investment decisions. It provides pharmaceutical companies, biotechnology organizations, investors and research institutions with a focused overview of the evolving CLDN18.2 targeted immunotherapy landscape and the competitive opportunities shaping gastric and gastroesophageal junction cancer treatment.
For more information about this report visit https://www.researchandmarkets.com/r/obc9x7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
